John Khoury: The CGT developers who adapt new manufacturing techniques early will lead later

About this episode

John Khoury discusses the importance of early investment in manufacturing techniques for CGT companies.

In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes John Khoury, Founder of Project Farma, to unpack how the standards for advanced therapies are shifting. John reflects on why infrastructure planning, automation, and comparability studies can’t be left until late-stage development. They explore how CGT companies can reduce manufacturing risk by running development activities in parallel, why early investment in platform approaches matters, and how outdated assumptions about regulatory flexibility may be slowing progress. For developers aiming to compete at scale, these early decisions are quickly becoming non-negotiable. Connect with John: https://www.linkedin.com/in/john-khoury-017b592/

People in this episode

Host: Jason C. Foster

Guest: John Khoury

Topics covered

• advanced therapies
• manufacturing techniques
• infrastructure planning
• automation
• regulatory flexibility
• CGT companies

Keywords

• CGT
• manufacturing risk
• development activities
• platform approaches
• regulatory standards

Mentioned in this episode

Organizations: Project Farma

More episodes of Ori Spotlight

• Ken Harris: Why AI and automation are CGT’s next inflection point · January 27, 2026 · 1h 3m
• Joe DePinto: Why advanced therapies need a new delivery model · January 13, 2026 · 1h 5m
• Jonathan Gluck: A personal account of navigating myeloma and CAR-T therapy · December 16, 2025 · 56 min
• Warner Biddle: Building a commercial model for CAR-T in autoimmune care · September 2, 2025 · 41 min
• Lavakumar Karyampudi: Building early-phase CGT infrastructure for translational success · August 12, 2025 · 1h 0m
• Henrik Andersen: How smart planning helps CGT scale further, faster · July 15, 2025 · 54 min